Literature DB >> 27417180

An Automated High-Throughput Metabolic Stability Assay Using an Integrated High-Resolution Accurate Mass Method and Automated Data Analysis Software.

Pranav Shah1, Edward Kerns1, Dac-Trung Nguyen1, R Scott Obach1, Amy Q Wang1, Alexey Zakharov1, John McKew1, Anton Simeonov1, Cornelis E C A Hop1, Xin Xu2.   

Abstract

Advancement of in silico tools would be enabled by the availability of data for metabolic reaction rates and intrinsic clearance (CLint) of a diverse compound structure data set by specific metabolic enzymes. Our goal is to measure CLint for a large set of compounds with each major human cytochrome P450 (P450) isozyme. To achieve our goal, it is of utmost importance to develop an automated, robust, sensitive, high-throughput metabolic stability assay that can efficiently handle a large volume of compound sets. The substrate depletion method [in vitro half-life (t1/2) method] was chosen to determine CLint The assay (384-well format) consisted of three parts: 1) a robotic system for incubation and sample cleanup; 2) two different integrated, ultraperformance liquid chromatography/mass spectrometry (UPLC/MS) platforms to determine the percent remaining of parent compound, and 3) an automated data analysis system. The CYP3A4 assay was evaluated using two long t1/2 compounds, carbamazepine and antipyrine (t1/2 > 30 minutes); one moderate t1/2 compound, ketoconazole (10 < t1/2 < 30 minutes); and two short t1/2 compounds, loperamide and buspirone (t½ < 10 minutes). Interday and intraday precision and accuracy of the assay were within acceptable range (∼12%) for the linear range observed. Using this assay, CYP3A4 CLint and t1/2 values for more than 3000 compounds were measured. This high-throughput, automated, and robust assay allows for rapid metabolic stability screening of large compound sets and enables advanced computational modeling for individual human P450 isozymes. U.S. Government work not protected by U.S. copyright.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27417180      PMCID: PMC5034701          DOI: 10.1124/dmd.116.072017

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  21 in total

1.  Automation of metabolic stability studies in microsomes, cytosol and plasma using a 215 Gilson liquid handler.

Authors:  J M Linget; P du Vignaud
Journal:  J Pharm Biomed Anal       Date:  1999-05       Impact factor: 3.935

2.  Development of an automated mass spectrometry system for the quantitative analysis of liver microsomal incubation samples: a tool for rapid screening of new compounds for metabolic stability.

Authors:  W A Korfmacher; C A Palmer; C Nardo; K Dunn-Meynell; D Grotz; K Cox; C C Lin; C Elicone; C Liu; E Duchoslav
Journal:  Rapid Commun Mass Spectrom       Date:  1999       Impact factor: 2.419

Review 3.  Application of a convective-dispersion model to predict in vivo hepatic clearance from in vitro measurements utilizing cryopreserved human hepatocytes.

Authors:  Ryan Niro; James P Byers; Ronald L Fournier; Kenneth Bachmann
Journal:  Curr Drug Metab       Date:  2003-10       Impact factor: 3.731

4.  Development and validation of k-nearest-neighbor QSPR models of metabolic stability of drug candidates.

Authors:  Min Shen; Yunde Xiao; Alexander Golbraikh; Vijay K Gombar; Alexander Tropsha
Journal:  J Med Chem       Date:  2003-07-03       Impact factor: 7.446

5.  Comparison of the use of liver models for predicting drug clearance using in vitro kinetic data from hepatic microsomes and isolated hepatocytes.

Authors:  Kiyomi Ito; J Brian Houston
Journal:  Pharm Res       Date:  2004-05       Impact factor: 4.200

Review 6.  Improving the decision-making process in the structural modification of drug candidates: enhancing metabolic stability.

Authors:  Alaa-Eldin F Nassar; Amin M Kamel; Caroline Clarimont
Journal:  Drug Discov Today       Date:  2004-12-01       Impact factor: 7.851

7.  Predicting human liver microsomal stability with machine learning techniques.

Authors:  Yojiro Sakiyama; Hitomi Yuki; Takashi Moriya; Kazunari Hattori; Misaki Suzuki; Kaoru Shimada; Teruki Honma
Journal:  J Mol Graph Model       Date:  2007-06-27       Impact factor: 2.518

8.  Structure-activity relationships of 1-alkyl-5-(3,4-dichlorophenyl)- 5-[2-[(3-substituted)-1-azetidinyl]ethyl]-2-piperidones. 1. Selective antagonists of the neurokinin-2 receptor.

Authors:  A Roderick MacKenzie; Allan P Marchington; Donald S Middleton; Sandra D Newman; Barry C Jones
Journal:  J Med Chem       Date:  2002-11-21       Impact factor: 7.446

Review 9.  Cytochrome P-450 3A4: regulation and role in drug metabolism.

Authors:  F P Guengerich
Journal:  Annu Rev Pharmacol Toxicol       Date:  1999       Impact factor: 13.820

Review 10.  Cytochrome p450 and chemical toxicology.

Authors:  F Peter Guengerich
Journal:  Chem Res Toxicol       Date:  2007-12-06       Impact factor: 3.739

View more
  15 in total

1.  Inhibition of natriuretic peptide receptor 1 reduces itch in mice.

Authors:  Hans Jürgen Solinski; Patricia Dranchak; Erin Oliphant; Xinglong Gu; Thomas W Earnest; John Braisted; James Inglese; Mark A Hoon
Journal:  Sci Transl Med       Date:  2019-07-10       Impact factor: 17.956

2.  Structure-Based Optimization of Small Molecule Human Galactokinase Inhibitors.

Authors:  Li Liu; Manshu Tang; Rajan Pragani; Frank G Whitby; Ya-Qin Zhang; Bijina Balakrishnan; Yuhong Fang; Surendra Karavadhi; Dingyin Tao; Christopher A LeClair; Matthew D Hall; Juan J Marugan; Matthew Boxer; Min Shen; Christopher P Hill; Kent Lai; Samarjit Patnaik
Journal:  J Med Chem       Date:  2021-09-07       Impact factor: 7.446

3.  Identification of Selective CYP3A7 and CYP3A4 Substrates and Inhibitors Using a High-Throughput Screening Platform.

Authors:  Md Kabir; Elias C Padilha; Pranav Shah; Ruili Huang; Srilatha Sakamuru; Eric Gonzalez; Lin Ye; Xin Hu; Mark J Henderson; Menghang Xia; Xin Xu
Journal:  Front Pharmacol       Date:  2022-07-01       Impact factor: 5.988

4.  Discovery and Structure-Activity Relationship Study of (Z)-5-Methylenethiazolidin-4-one Derivatives as Potent and Selective Pan-phosphatidylinositol 5-Phosphate 4-Kinase Inhibitors.

Authors:  Theresa D Manz; Sindhu Carmen Sivakumaren; Fleur M Ferguson; Tinghu Zhang; Adam Yasgar; Hyuk-Soo Seo; Scott B Ficarro; Joseph D Card; Hyeseok Shim; Chandrasekhar V Miduturu; Anton Simeonov; Min Shen; Jarrod A Marto; Sirano Dhe-Paganon; Matthew D Hall; Lewis C Cantley; Nathanael S Gray
Journal:  J Med Chem       Date:  2020-04-27       Impact factor: 7.446

5.  Preclinical Pharmacological Development of Chlorcyclizine Derivatives for the Treatment of Hepatitis C Virus Infection.

Authors:  Adam Rolt; Derek Le; Zongyi Hu; Amy Q Wang; Pranav Shah; Marc Singleton; Emma Hughes; Andrés E Dulcey; Shanshan He; Michio Imamura; Takuro Uchida; Kazuaki Chayama; Xin Xu; Juan J Marugan; T Jake Liang
Journal:  J Infect Dis       Date:  2018-05-05       Impact factor: 5.226

6.  Design, Synthesis, and Biological Evaluation of Quinazolin-4-one-Based Hydroxamic Acids as Dual PI3K/HDAC Inhibitors.

Authors:  Ashish Thakur; Gregory J Tawa; Mark J Henderson; Carina Danchik; Suiyang Liu; Pranav Shah; Amy Q Wang; Garrett Dunn; Md Kabir; Elias C Padilha; Xin Xu; Anton Simeonov; Surender Kharbanda; Richard Stone; Gurmit Grewal
Journal:  J Med Chem       Date:  2020-04-08       Impact factor: 7.446

7.  Small Molecule Inhibitors of Activation-Induced Deaminase Decrease Class Switch Recombination in B Cells.

Authors:  Juan Alvarez-Gonzalez; Adam Yasgar; Robert W Maul; Amanda E Rieffer; Daniel J Crawford; Daniel J Salamango; Dorjbal Dorjsuren; Alexey V Zakharov; Daniel J Jansen; Ganesha Rai; Juan Marugan; Anton Simeonov; Reuben S Harris; Rahul M Kohli; Patricia J Gearhart
Journal:  ACS Pharmacol Transl Sci       Date:  2021-05-07

8.  Discovery and Optimization of 2H-1λ2-Pyridin-2-one Inhibitors of Mutant Isocitrate Dehydrogenase 1 for the Treatment of Cancer.

Authors:  Jason M Rohde; Surendra Karavadhi; Rajan Pragani; Li Liu; Yuhong Fang; Weihe Zhang; Andrew McIver; Hongchao Zheng; Qingyang Liu; Mindy I Davis; Daniel J Urban; Tobie D Lee; Dorian M Cheff; Melinda Hollingshead; Mark J Henderson; Natalia J Martinez; Kyle R Brimacombe; Adam Yasgar; Wei Zhao; Carleen Klumpp-Thomas; Sam Michael; Joseph Covey; William J Moore; Gordon M Stott; Zhuyin Li; Anton Simeonov; Ajit Jadhav; Stephen Frye; Matthew D Hall; Min Shen; Xiaodong Wang; Samarjit Patnaik; Matthew B Boxer
Journal:  J Med Chem       Date:  2021-04-06       Impact factor: 7.446

9.  Optimization of ether and aniline based inhibitors of lactate dehydrogenase.

Authors:  Plamen P Christov; Kwangho Kim; Somnath Jana; Ian M Romaine; Ganesha Rai; Bryan T Mott; Alexander A Allweil; Alexander Lamers; Kyle R Brimacombe; Daniel J Urban; Tobie D Lee; Xin Hu; Christine M Lukacs; Douglas R Davies; Ajit Jadhav; Matthew D Hall; Neal Green; William J Moore; Gordon M Stott; Andrew J Flint; David J Maloney; Gary A Sulikowski; Alex G Waterson
Journal:  Bioorg Med Chem Lett       Date:  2021-03-24       Impact factor: 2.940

10.  Assessing inhibitors of mutant isocitrate dehydrogenase using a suite of pre-clinical discovery assays.

Authors:  Daniel J Urban; Natalia J Martinez; Mindy I Davis; Kyle R Brimacombe; Dorian M Cheff; Tobie D Lee; Mark J Henderson; Steven A Titus; Rajan Pragani; Jason M Rohde; Li Liu; Yuhong Fang; Surendra Karavadhi; Pranav Shah; Olivia W Lee; Amy Wang; Andrew McIver; Hongchao Zheng; Xiaodong Wang; Xin Xu; Ajit Jadhav; Anton Simeonov; Min Shen; Matthew B Boxer; Matthew D Hall
Journal:  Sci Rep       Date:  2017-10-06       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.